A study monitoring clinical course of Idiopathic Pulmonary Fibrosis in a real‑world setting over 5 years: PROOF registry

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 23 Sep 2019

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Acetylcysteine (Primary) ; Corticosteroids (Primary) ; Nintedanib (Primary) ; Pirfenidone (Primary)
Indications Idiopathic pulmonary fibrosis
Focus Therapeutic Use
Sponsors Genentech; Roche

22 May 2019 Status changed from recruiting to completed, according to the trial design presented at the 115th International Conference of the American Thoracic Society
22 May 2019 Trial design of the PROOF NEXT registry (n=382), presented at the 115th International Conference of the American Thoracic Society
19 Sep 2018 Results (n=233) assessing functional decline over time when treated with pirfenidone, presented at the 28th Annual Congress of the European Respiratory Society.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com